Government-approved research is showing that psychedelic therapy can help people suffering from serious mental health conditions, especially those for whom other treatments have failed. The world’s largest-ever clinical trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) is almost complete, and the results will help make MDMA-assisted psychotherapy the first legal psychedelic treatment by 2021.
MAPS has already raised over $1.3 million for this study through contributions from individuals, private foundations, and our previous crowdfunding campaign. We’re asking you to help us raise the remaining $50,000.
By making a donation and sharing this campaign, you help:
- Make MDMA-assisted psychotherapy a legal treatment by 2021
- Complete a crucial study of MDMA-assisted psychotherapy for veterans, firefighters, and police officers with PTSD
- Demonstrate growing public support for psychedelic and medical marijuana research
Legalizing psychedelic therapy is not the same as legalizing psychedelics for all uses. We are completing the research necessary to develop psychedelic therapy into a legal prescription treatment.
Psychedelic therapy is not a take-home drug. Psychedelic therapy must be conducted in a therapeutic environment with proper support.
MAPS’ non-profit drug development research needs your support because neither the pharmaceutical industry, the government, nor major foundations have yet been willing to invest in psychedelic therapy research.